TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35066957

Group type: EXPERIMENTAL
Intervention: Education about cervical cancer and Pap smear test (face-to-face interviews using Turkish sign language)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Education about cervical cancer and Pap smear test
Number of subjects: 156
Study: 34343161

Group type: EXPERIMENTAL
Intervention: Early stoma closure (2 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Late stoma closure (12 weeks)
Number of subjects: 71
Study: 32956008

Group type: EXPERIMENTAL
Intervention: Lidcombe Program without verbal contingencies
Number of subjects: 74

Group type: COMPARATOR
Intervention: Lidcombe Program with verbal contingencies
Number of subjects: 74
Study: 35253721

Group type: EXPERIMENTAL
Intervention: Specific neck stabilization
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Specific core stabilization
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combined stabilization practices
Number of subjects: 102
Study: 33208641

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) combined with conventional bupivacaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (conventional bupivacaine combined with dexamethasone)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine with dexamethasone and conventional bupivacaine (LBD group)
Number of subjects: 76
Study: 34214736

Group type: EXPERIMENTAL
Intervention: Fractionated HPC infusion (4 × 10^6 CD34+ cells/kg on day 0, remaining cells infused on days 2, 4, and 6)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Bulk HPC infusion (7 × 10^6 CD34+ cells/kg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fractionated HPC infusion
Number of subjects: 74

Group type: COMPARATOR
Intervention: Bulk HPC infusion
Number of subjects: 74
Study: 35135986

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 800 mg daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 34959909

Group type: EXPERIMENTAL
Intervention: True information about fluid losses
Number of subjects: 11

Group type: COMPARATOR
Intervention: False information about fluid losses
Number of subjects: 11
Study: 32213013

Group type: EXPERIMENTAL
Intervention: 19-gauge stainless steel needle
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 19-gauge nitinol-based needle
Number of subjects: 46
Study: 35642697

Group type: EXPERIMENTAL
Intervention: Core stability exercise program (30 min, in addition to standard physical therapy program)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard physical therapy program (1 h per session, three times weekly)
Number of subjects: 40
Study: 34118568

Group type: EXPERIMENTAL
Intervention: SAP block group (n = 43)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study: 32384874

Group type: EXPERIMENTAL
Intervention: LTBI treatment (specific regimen not detailed)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 63
Study: 35549538

Group type: EXPERIMENTAL
Intervention: Escitalopram (8-week treatment)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 89
Study: 34070321

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 663
Study: 32293921

Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Injectable glucagon (IG)
Number of subjects: 65
Study: 33991554

Group type: EXPERIMENTAL
Intervention: Pressure-controlled volume guaranteed mode (Group PCVG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Volume-controlled mode (Group VC)
Number of subjects: 30
Study: 33772825

Group type: EXPERIMENTAL
Intervention: Dalteparin prophylaxis
Number of subjects: 117

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 117
Study: 34360103

Group type: EXPERIMENTAL
Intervention: Core stabilization exercise with abdominal drawing-in maneuver technique (CSE with ADIM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: General strengthening exercise (STE)
Number of subjects: 34
Study: 36375341

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 256
Study: 33387391

Group type: EXPERIMENTAL
Intervention: 2D video glasses
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: VR glasses
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control
Number of subjects: 141
Study: 36008895

Group type: EXPERIMENTAL
Intervention: Gouty Tea, 1 bag/time, tid, for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Allopurinol orally, 100 mg/time, tid, for 12 weeks
Number of subjects: 120
Study: 32273085

Group type: EXPERIMENTAL
Intervention: High Velocity Nasal Insufflation (HVNI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-Invasive Positive Pressure Ventilation (NIPPV)
Number of subjects: 65
Study: 34569480

Group type: EXPERIMENTAL
Intervention: Imaginal retraining (training group)
Number of subjects: 345

Group type: COMPARATOR
Intervention: No training (no-training group)
Number of subjects: 345
Study: 32174297

Group type: EXPERIMENTAL
Intervention: Helping Families Programme‐Modified
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 48
Study: 35339323

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP) with traditional rehabilitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 20
Study: 36229155

Group type: EXPERIMENTAL
Intervention: Healthy Habits Triple P - Oral health (web-based parenting intervention)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (oral health-related information published by Australian oral health agencies)
Number of subjects: 18
Study: 34167929

Group type: EXPERIMENTAL
Intervention: His‐CRT
Number of subjects: 50

Group type: COMPARATOR
Intervention: BiV‐CRT
Number of subjects: 50
Study: 32228315

Group type: EXPERIMENTAL
Intervention: Pazopanib (600 mg orally daily in 2 divided doses, 400 and 200 mg) and cyclophosphamide (50 mg orally daily for 21 days every 28 days)
Number of subjects: 20
Study: 33523907

Group type: EXPERIMENTAL
Intervention: Polygenic risk score approach
Number of subjects: 78500

Group type: EXPERIMENTAL
Intervention: Genomic risk mapping
Number of subjects: 78500

Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian randomization
Number of subjects: 78500
Study: 34520104

Group type: EXPERIMENTAL
Intervention: Exercise + Protein (EP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protein (P)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 100
Study: 32926573

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Azithromycin
Number of subjects: 377

Group type: COMPARATOR
Intervention: Hydroxychloroquine alone
Number of subjects: 377

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 377
Study: 34922567

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure plus rescue medication (RM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rescue medication (RM) alone
Number of subjects: 41
Study: 32764634

Group type: EXPERIMENTAL
Intervention: Oral probiotic lozenges containing Streptococcus salivarius M18
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 33998292

Group type: EXPERIMENTAL
Intervention: Exercise (60 min at 65% VO2max)
Number of subjects: 12
Study: 32555211

Group type: EXPERIMENTAL
Intervention: Comfort blankets (tactile enrichment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Music (auditory enrichment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paro robot (multi-sensory enrichment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 34545437

Group type: EXPERIMENTAL
Intervention: Laterally closed tunnel technique + photobiomodulation (660 nm diode, 3.5 J/cm2 per point)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Laterally closed tunnel technique + photobiomodulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Laterally closed tunnel technique + sham laser
Number of subjects: 19
Study: 33779057

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine as prophylaxis for COVID-19
Number of subjects: 0
Study: 33048300

Group type: EXPERIMENTAL
Intervention: Itolizumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35964061

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 34312191

Group type: EXPERIMENTAL
Intervention: Tipping Point Programme (TPP)
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: TPP+ with emphasised social norms change
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1242
Study: 33207935

Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg/day, with a 2-week titration)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 100
Study: 35843465

Group type: EXPERIMENTAL
Intervention: His-bundle pacing (HBP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Biventricular pacing (BVP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both HBP and BVP
Number of subjects: 50
Study: 32306083

Group type: EXPERIMENTAL
Intervention: High-precision image-guided single-session radiosurgery with 25 Gy
Number of subjects: 20
Study: 35148195

Group type: EXPERIMENTAL
Intervention: YES-10 (200 mg, 2 capsules daily for 4 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (2 capsules daily for 4 weeks)
Number of subjects: 72
Study: 33004235

Group type: EXPERIMENTAL
Intervention: Care Consultation
Number of subjects: 445
Study: 35143970

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 82
Study: 33549836

Group type: EXPERIMENTAL
Intervention: FRUIT+DGV smoothie condition
Number of subjects: 68

Group type: COMPARATOR
Intervention: FRUIT ONLY smoothie condition
Number of subjects: 68
Study: 36341230

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE) for strong appetite group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (non-acupoint catgut embedding) for strong appetite group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE) for moderate appetite group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (non-acupoint catgut embedding) for moderate appetite group
Number of subjects: 123
Study: 32009286

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newer glucose-lowering medications (sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists)
Number of subjects: 0
Study: 35970013

Group type: EXPERIMENTAL
Intervention: Multiagent induction chemotherapy (ICT; nab-paclitaxel/gemcitabine alone or nab-paclitaxel/gemcitabine followed by FOLFIRINOX) for 16 weeks
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Multiagent induction chemotherapy (ICT) with robust CA 19-9 response (decrease to ≤50 U/ml)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: R0 resection (n=31; 23%)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: R1 resection (n=14; 11%)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: CA 19-9 response after ICT
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: CA 19-9 decrease to ≤61 U/ml as optimal cut-off
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: CA 19-9 nonresponders (<20% decrease or increase)
Number of subjects: 165
Study: 36224406

Group type: EXPERIMENTAL
Intervention: Laparoscopic TaTME
Number of subjects: 116

Group type: COMPARATOR
Intervention: Laparoscopic LaTME
Number of subjects: 116
Study: 34031138

Group type: EXPERIMENTAL
Intervention: Veverimer
Number of subjects: 0
Study: 32386521

Group type: EXPERIMENTAL
Intervention: PCOS+0.5g/kg Gln
Number of subjects: 40

Group type: COMPARATOR
Intervention: PCOS group
Number of subjects: 40
Study: 33779938

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 2030

Group type: COMPARATOR
Intervention: Placebo 10 mg once daily
Number of subjects: 2030
Study: 33559973

Group type: EXPERIMENTAL
Intervention: Pedaling for Parkinson's ™ (PFP) program
Number of subjects: 0
Study: 36195320

Group type: EXPERIMENTAL
Intervention: Curcumin mixed with solid lipid curcumin particle (SLCP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Curcumin mixed with squalene (CSQU)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Curcumin mixed with docosahexaenoic acid (CDHA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standardized unformulated curcumin extract (StdC)
Number of subjects: 10
Study: 32341031

Group type: EXPERIMENTAL
Intervention: Cabazitaxel or cabazitaxel and carboplatin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CTC analysis
Number of subjects: 47
Study: 34710363

Group type: EXPERIMENTAL
Intervention: Supervised primaquine treatment (0.5 mg/kg per day for 14 days, supervised on alternate days)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Unsupervised primaquine treatment (0.5 mg/kg per day for 14 days, unsupervised)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Supervised primaquine treatment
Number of subjects: 419

Group type: COMPARATOR
Intervention: Unsupervised primaquine treatment
Number of subjects: 419
Study: 33555626

Group type: EXPERIMENTAL
Intervention: VR-based documents (VRdocs)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group education documents
Number of subjects: 77
Study: 36196180

Group type: EXPERIMENTAL
Intervention: Low-dose hydroxyurea
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Moderate-dose hydroxyurea
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: State-supported stroke screening service and treatment
Number of subjects: 20000
Study: 33693945

Group type: EXPERIMENTAL
Intervention: MUFA-rich meals
Number of subjects: 32

Group type: COMPARATOR
Intervention: SFA-rich meals
Number of subjects: 32

Group type: COMPARATOR
Intervention: n-6 PUFA-rich meals
Number of subjects: 32
Study: 32689849

Group type: EXPERIMENTAL
Intervention: Ringer’s lactate (RL) group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) group
Number of subjects: 96
Study: 35363161

Group type: EXPERIMENTAL
Intervention: Acupuncture (40 sessions for 16 weeks with usual care)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (regular meals, sufficient sleep, and appropriate exercise)
Number of subjects: 60
Study: 33327727

Group type: EXPERIMENTAL
Intervention: Active-controlled antidiabetic or antiplatelet medications
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo-controlled antidiabetic or antiplatelet medications
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active comparators
Number of subjects: 10

Group type: COMPARATOR
Intervention: Second-generation sulfonylureas as a proxy for placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall RWE findings
Number of subjects: 10
Study: 36053298

Group type: EXPERIMENTAL
Intervention: Oral OXT (24IU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intranasal OXT
Number of subjects: 80
Study: 33356529

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/day) plus androgen deprivation therapy
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Placebo plus androgen deprivation therapy
Number of subjects: 1146
Study: 34775518

Group type: EXPERIMENTAL
Intervention: 3.0% hydrogen peroxide (HP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1.5% hydrogen peroxide (HP) + Germinator
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3.0% hydrogen peroxide (HP) + Germinator
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) + Germinator
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Germinator
Number of subjects: 64

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1.5% hydrogen peroxide (HP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX)
Number of subjects: 64
Study: 33351921

Group type: EXPERIMENTAL
Intervention: Lifestyle therapy plus testosterone (LT+Test)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lifestyle therapy plus placebo (LT+Pbo)
Number of subjects: 83
Study: 35594514

Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Flexible fixation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Uninjured ankles
Number of subjects: 13
Study: 33300209

Group type: EXPERIMENTAL
Intervention: Leucocyte-Rich Platelet-Rich Plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 0
Study: 32174449

Group type: EXPERIMENTAL
Intervention: Running at 8 km/h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Competitive runners
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Recreational runners
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Novice runners
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 31
Study: 36347265

Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1137
Study: 34769633

Group type: EXPERIMENTAL
Intervention: EVOO + DieTBra
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: DieTBra
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: EVOO
Number of subjects: 149
Study: 33361029

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg every 12 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisone (20 mg once daily for 2 weeks)
Number of subjects: 60
Study: 35717989

Group type: EXPERIMENTAL
Intervention: Liso-cel (100 × 10^6 CAR+ T cells intravenously)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard of care (salvage immunochemotherapy followed by autologous HSCT)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Liso-cel
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 184
Study: 32445215

Group type: EXPERIMENTAL
Intervention: MPC group (Microwave ablation combined with cisplatin plus gemcitabine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: MGC group (Microwave ablation combined with gemcitabine plus pemetrexed)
Number of subjects: 100
Study: 34118301

Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 19867

Group type: COMPARATOR
Intervention: Arteriovenous graft (AVG)
Number of subjects: 19867
Study: 34898943

Group type: EXPERIMENTAL
Intervention: Meditation and breathing exercises
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 84
Study: 34677081

Group type: EXPERIMENTAL
Intervention: Fitbit and Facebook-based PA intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fitbit only (Control)
Number of subjects: 50
Study: 32954942

Group type: EXPERIMENTAL
Intervention: Training group (N = 128)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Waitlist control group (N = 117)
Number of subjects: 245
Study: 34016085

Group type: EXPERIMENTAL
Intervention: Routine antenatal screening ultrasound (US)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ultrasound ANC visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-risk pregnancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antenatal screening US
Number of subjects: 0
Study: 32514820

Group type: EXPERIMENTAL
Intervention: 15 g or 30 g 10% trehalose solution administered weekly via IV
Number of subjects: 14
Study: 35094377

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy (LSCP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sacrospinous ligament fixation (SSLF)
Number of subjects: 32
Study: 35080016

Group type: EXPERIMENTAL
Intervention: Tele‐Savvy (active condition)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Healthy Living (attention control)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 111
Study: 32285809

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Standard therapy (ST)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 110
Study: 35899435

Group type: EXPERIMENTAL
Intervention: CYP2D6-guided opioid prescribing with clinical decision support (CDS) for postoperative pain management (intervention arm)
Number of subjects: 2020

Group type: COMPARATOR
Intervention: Delayed testing without clinical decision support (control arm)
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: CYP2D6-guided opioid prescribing (intervention arm)
Number of subjects: 2020
Study: 34063665

Group type: EXPERIMENTAL
Intervention: High Volume (HV: 5 sets of 10 reps at 70% of 1 repetition maximum (1RM))
Number of subjects: 11

Group type: COMPARATOR
Intervention: High Intensity (HI: 5 sets of 3 reps at 90% of 1RM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High Volume (HV)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High Intensity (HI)
Number of subjects: 11
Study: 32947423

Group type: EXPERIMENTAL
Intervention: levobupivacaine + nalbuphine
Number of subjects: 48

Group type: COMPARATOR
Intervention: levobupivacaine + dexmedetomidine
Number of subjects: 48
Study: 35172587

Group type: EXPERIMENTAL
Intervention: Xevinapant plus standard‐of‐care cisplatin‐based chemoradiotherapy (CRT)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Xevinapant monotherapy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Xevinapant or placebo plus standard‐of‐care CRT
Number of subjects: 700
Study: 34574676

Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 50% O2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 100% O2 (HBO) at 1.5 ATA
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 100% O2 (HBO) at 2.5 ATA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 36067925

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 47